Authors
Nadezhdin A. V.
PhD, Department Head1
Tetenova E. Ju.
PhD, Leading Researcher1
Sharova E. V.
Head, Department for emergency narcological care with an anesthesia-resuscitation unit1
1 - Moscow Research and Practical Centre for Narcology of the Department of Public Health, 109390, Moscow, Ljublinskaya ul. 37/1
Abstract
The paper presents the diagnostic criteria of ICD-10 for major morbid conditions associated with the use of nicotine. Authors consider health and social consequences of tobacco use by means of pipes and hookahs, harm associated with passive smoking, use of electronic cigarettes and smokeless forms of tobacco. Principal tools for the diagnosis of the degree of dependence syndrome and readiness to quit, as well as modern treatment methods are presented.
Key words
Tobacco dependence, tobacco use, nicotine dependence, electronic cigarettes, passive smoking, nicotine replacement therapy, Fagerstrom test
References
1. Antonov N.S., Saharova G.M., Donitova V.V., Kotov A.A., Berezhnova I.A., Latif E, «Electronic cigarettes: evaluation of safety and health risks.» Pulmonologiya 3 (2014): 122-27.
2. VCIOM, Press release ¹ 3116. Accessed at: http://wciom.ru/index.php?id=236&uid=115711
3. WHO report on global tobacco epidemic, 2009: implementing smoke-free environments. Accessed at: http://whqlibdoc.who.int/publications/2010/9789244563915_rus.pdf
4. Report on tobacco dependence and cessation (in accordance with Article 14 of Convention (FCTC/COP 2 (14)). WHO, 2008. Print.
5. Instructions for use of Wellbutrin. State Register of Medicinal Products. Accessed at: http://grls.rosminzdrav.ru/InstrImgMZ.aspx?regNr=ĖŃŠ-008003/10&page=2
6. Kukes V.G., Marinin V.F., Gavrisyuk E.V, «Varenicline – the new generation drug for the treatment of tobacco dependence.» Klinicheskaya farmakologiya i terapiya 3 (2009): 1-5.
7. Levshin V.F, Tobacco dependence: pathogenesis, diagnosis and treatment. Moscow: IMA-PRESS, 2012. Print.
8. Levshin V.F., Slepchenko N.I., Radkevich N.V, «A randomized controlled efficacy study of Tabeks® (cytisine) for the treatment of tobacco dependence.» Voprosy narkologii 5 (2009): 13-22.
9. Mahov M.A, «Measuring tools for tobacco dependence.» Narkologiya 3 (2015): 46-57.
10. Mahov M.A., Nadezhdin A.V, «Clinical features of tobacco dependence in patients with alcohol addiction.» Narkologiya 1 (2016): 39-50.
11. Nadezhdin A.V., Tetenova E.Yu., Zekrina N.A., Kolgashkin A.Yu, «Treatment and diagnosis of nicotine dependence.» Narkologiya 10 (2011): 84-94.
12. Smoking cessation and treatment of tobacco dependence. Evidence-based recommendations edited by Professor A.K. Demin. Moscow – Washington DC. Moscow: RAPSIGO, 2013. Print.
13. WHO Framework Convention on Tobacco Control. Accessed at: http://www.who.int/fctc/whofctc_cover_russian.pdf
14. Saharova G.M., Antonov N.S, Facilitating smoking cessation in therapeutic practice. Textbook. Moscow: UP Print, 2010. Print.
15. Saharova G.M., Antonov N.S, «The harmful effects of smoking on health and the approaches to the treatment of tobacco dependence.» Spravochnik poliklinicheskogo vracha 14-15 (2008): 16-20.
16. Federal Law of 23 February 2013 N 15-FZ «On the Protection of the health of citizens from exposure to tobacco smoke and the consequences of tobacco use.» Accessed at: https://rg.ru/2013/02/26/zakon-dok.html
17. Federal Law of the Russian Federation of 22.12.2008 number 268-FZ «Technical Regulations on Tobacco Products.» Accessed at: http://www.rg.ru/2008/12/26/tabak-dok.html
18. «Public Opinion» Foundation (24-25.10.2015). On smoking and breath. Accessed at: http://fom.ru/Zdorove-i-sport/12483
19. Churkin A.A., Martyushov A.N, Quick guide to using the ICD-10 in mental health and addiction. Moscow: Triada-X, 1999. Print.
20. Chuchalin A.G., Saharova G.M., Antonov N.S., Zajceva O.Yu., Novikov K.Yu, Comprehensive treatment of tobacco dependence and prevention of chronic obstructive pulmonary disease caused by tobacco smoking. Methodical guidelines of the Ministry of Health and Social Development. Moscow, 2002. Print.
21. Baker T.B., Breslau N., Covey L., Shiffman S. «DSM Criteria for Tobacco Use Disorder and Tobacco Withdrawal: A Critique and Proposed Revisions for DSM-5.» Addiction 2 (2013): 263-75. doi: 10.1111/j.1360-0443.2011.03657.x.
22. Baker Ņ.B., Piper M.E., McCarthy D.E., Bolt D.M., et al. «Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependence.» Nicotine Tob. Res. 4 (2007): 555-70. doi: 10.1080/14622200701673480.
23. Bam T. S., Bellew W., Berezhnova I., Jackson-Morris A., Jones A., Latif E., Molinari M. A., Quan G., Singh R. J., Wisotzky M. «Position statement on electronic cigarettes or electronic nicotine delivery systems.» International Union Against Tuberculosis and Lung Disease 1 (2014): 5-7.
24. Benowitz N.L. «Cotinine as a Biomarker of Environmental Tobacco Smoke Exposure.» Epidemiol. Rev. 2 (1996): 188-204.
25. Benowitz N.L., Hukkanen J., Jacob P., «Nicotine Chemistry, Metabolism, Kinetics and Biomarkers.» Handbook of Experimental Pharmacology Vol.192 (2009): 29-60.
26. Bloom J., Hinrichs A.L., Wang J.C., von Weymarn L.B., Kharasch E.D., Bierut L.J., Goate A., Murphy S.E. «The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.» Pharmacogenet Genomics. 7 (2011): 403-16. doi: 10.1097/FPC.0b013e328346e8c0.
27. Chaouachi K. «Use & Misuse of Water-filtered Tobacco Smoking Pipes in the World. Consequences for Public Health, Research & Research Ethics.» Open Med Chem. J. 9 (2015): 1-12. doi: 10.2174/1874104501509010001/.
28. Clinical guidelines and procedures for the management of nicotine dependent inpatients. Department of Health, Western Australia. 2011. P. 2. Print.
29. Clinical guidelines and procedures for the management of nicotine dependent inpatients. Department of Health, Western Australia. 2011. P. 9. Print.
30. Diagnostic and statistical manual of mental disorders: DSM-IV. – 4th ed. American Psychiatric Association – Washington, – 1994. Print.
31. El-Zaatari Z.M. Chami H.A., Zaatari G.S. «Health effects associated with waterpipe smoking.» Tob. Control. 1 (2015): 31-43. doi: 10.1136/tobaccocontrol-2014-051908.
32. Fagerstrom K.O., Schneider N. «Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire.» J. Behav. Med. 12 (1989): 159-182.
33. Fiore M.C., Bailey W.C., Cohen S.J., et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. – Rockville, Md: US Department of Health and Human Services. Public Health Service. – 2000. Print.
34. Flouris A.D., Vardavas C.I., Metsios G.S., Tsatsakis A.M., Koutedakis Y. «Biological evidence for the acute health effects of secondhand smoke exposure.» American Journal of Physiology – Lung Cellular and Molecular Physiology 1 (2010): 3-12. doi: 10.1152/ajplung.00215.2009/.
35. Framework for the treatment of nicotine addiction. Perth: Health Networks Branch, Department of Health, Western Australia. – 2010. Print.
36. Global Heart 2012 / World Heart Federation (Geneva). 2 (2012). doi:10. 1016/j.gheart.2012.05.003.
37. Hashemipour M.A., Gholampour F., Fatah F., Bazregari S. «Snus (nass) and oral cancer: A case series report.» Dent Res J (Isfahan) 1 (2013): 116-21. doi: 10.4103/1735-3327.111813
38. International Agency for Research on Cancer. Vol. 89. Lyon, France: World Health Organization International Agency for Research on Cancer; IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; 2007. Smokeless Tobacco and Some Tobacco-Specific N-Nitrosamines.
39. Lee Š. «Summary of the epidemiological evidence relating snus to health.» Regul. Toxicol. Pharmacol. 59 (2011): 197-214.
40. Mayer B. «How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century.» Arch. Toxicol. 1 (2014): 5-7.
41. Meneses-Gaya I.C., Zuardi A.W., Loureiro S.R., Crippa J.A. «Psychometric properties of the Fagerström Test for Nicotine Dependence.» J Bras Pneumol. 1 (2009): 73-82.
42. Mishra A., Chaturvedi P., Datta S., Sinukumar S., Joshi P., Garg A. «Harmful effects of nicotine.» Indian J. Med Paediatr. Oncol. 1 (2015): 24-31. doi: 10.4103/0971-5851.151771.
43. Munarini Å., Marabelli C., Pozzi P., Boffi R. «Extended varenicline treatment in a severe cardiopathic cigarette smoker: a case report.» J. Med. Case Rep. V. 9:29 (2015). doi: 10.1186/1752-1947-9-29
44. Mushtaq N., Beebe L.A. «A review of the validity and reliability of smokeless tobacco dependence measures.» Addict. Behav. 4 (2012): 361-6. doi: 10.1016/j.addbeh.2011.12.003.
45. Nemmar A., Raza H., Yuvaraju P., Beegam S., John A., Yasin J., Rasheed S. et al. «Nose-only water-pipe smoking effects on airway resistance, inflammation, and oxidative stress in mice.» Journal of Applied Physiology 9 (2013): 1316-23 doi: 10.1152/japplphysiol.00194.2013.
46. Nicotine. IPCS INCHEM. Accessed at: http://www.inchem.org/documents/pims/chemical/nicotine.htm#PartTitle:1. NAME
47. NIDA Tobacco Addiction. – 2009. Accessed at: http://smoking.drugabuse.gov
48. Novotny T.E., Hardin S.N., Hovda L.R., Novotny D.J., McLean M.K., Khan S. «Tobacco and cigarette butt consumption in humans and animals.» Tob. Control. 1 (2011): 17-20. doi: 10.1136/tc.2011.043489.
49. Oliveira P.P, Sihler C.B., Moura L., et al. «First reported outbreak of green tobacco sickness in Brazil.» Cad. Saude Publica. 12 (2010): 2263-69.
50. Piliguian M., Zhu A.Z., Zhou Q., Benowitz N.L., Ahluwalia J.S., Sanderson Cox L., Tyndale R.F. «Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo.» Pharmacogenet. Genomics. 2 (2014): 118-28. doi: 10.1097/FPC.0000000000000026.
51. Raad D., Gaddam S., Schunemann H.J., Irani J., Abou Jaoude P., Honeine R., Akl E.A. «Effects of water-pipe smoking on lung function: a systematic review and meta-analysis.» Chest. 4 (2011): 764-74. doi: 10.1378/chest.10-0991.
52. Raupach T., Schayck C.P. «Pharmacotherapy for Smoking Cessation.» CNS Drugs 5 (2011): 371-82.
53. Satora L., Goszcz H., Gomółka E., Biedroń W. «Green tobacco sickness in Poland.» Pol. Arch. Med. Wewn. 3 (2009): 184-6.
54. Saxena K., Scheman A. «Suicide plan by nicotine poisoning: a review of nicotine toxicity.» Vet Hum Toxicol. 6 (1985): 495-7.
55. Smolinske S.C., Spoerke D.G., Spiller S.K., Wruk K.M., Kulig K., Rumack B.H. «Cigarette and nicotine chewing gum toxicity in children.» Hum Toxicol. 1 (1988): 27-31.
56. Stead L.F., Hartmann-Boyce J., Perera R., Lancaster T. «Telephone counselling for smoking cessation.» Cochrane Database Syst. Rev. – 2013. – 12;8:CD002850. doi: 10.1002/14651858.CD002850.pub3.
57. Stead L.F., Lancaster T. «Combined pharmacotherapy and behavioural interventions for smoking cessation.» Cochrane Database Syst Rev. – 2012. – Oct 17;10:CD008286. doi: 10.1002/14651858.CD008286.pub2.
58. The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014. – P.8-10. Print.
59. The ICD-10 Classification of Mental and Behavioural Disorders. Accessed at: http://www.who.int/classifications/icd/en/GRNBOOK.pdf?ua=1
60. Thomas K.H., Martin R.M., Knipe D.W., Higgins J.P., Gunnell D. «Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.» BMJ 2015. V. 12. ¹ 350:h1109. doi: 10.1136/bmj.h1109.
61. Tonstad S., Gustavsson G., Kruse E., Walmsley J.M., Westin A. «Symptoms of nicotine toxicity in subjects achieving high cotinine levels during nicotine replacement therapy.» Nicotine Tob. Res. 9 (2014): 1266-71. doi: 10.1093/ntr/ntu076. Epub 2014 May 22.
62. Treating Tobacco Use and Dependence: 2008 Update U.S. Department of Health and Human Services Public Health Service May 2008. Accessed at: http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf
63. Underner M., Perriot J., Peiffer G. «Smokeless tobacco.» Presse Med. 1 (2012): 3-9. doi: 10.1016/j.lpm.2011.06.005.
64. Varenicline (marketed as Chantix) Information//U.S. Food and Drug Administration. Accessed at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm106540.htm
65. Walker N., Howe C., Bullen C., McRobbie H., Glover M., et al «Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking.» BMC Public Health 11 (2011): 880. doi: 10.1186/1471-2458-11-880
66. Woolf A., Burkhart K., Caraccio T., Litovitz T. «Childhood poisoning involving transdermal nicotine patches.» Pediatrics 5 (1997): E4.
